This formula can be administered via IV, IM, or SubQ injection
Even so, despite the promising weight reduction efficacy of OXM, only a small number of development projects appears to be at an advanced stage
Unlike a sanctioned clinical trial (where experimental drugs can be used under careful monitoring and informed consent under an FDA Investigational New Drug protocol), offering BPC-157 in routine practice amounts to experimenting on the patient without oversight
[16] Moreover, there is a hypothesis that GHK-Cu might reduce the release of iron from ferritin
Our protocol adjustments for Fitzpatrick IV-V patients using the GHK-Cu stack include more conservative SkinPen depth settings, lower needle density on the first session, an extended recovery window between sessions compared to lighter skin types, consistent mineral sunscreen guidance beginning two weeks before the first session, and careful timing to avoid treating recently tanned skin
Toxicology studies in animals have shown BPC 157 to be safe even at high doses, with no clear toxic dose identified
